-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Benzinga·03/03/2025 15:43:24
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.